Vaccine‐Induced and Hybrid Immunity Against SARS‐CoV‐2 Variants of Concern in Two Cohorts in Queensland, Australia (2021–2022)
Rhys Parry(The University of Queensland), Alexander A. Khromykh(The University of Queensland), Lucy Burr(Mater Health Services), Alberto A. Amarilla(Commonwealth Scientific and Industrial Research Organisation), Julian D. J. Sng(The University of Queensland), Daniel Watterson(The University of Queensland), S. Thomas Kelly(RIKEN Center for Integrative Medical Sciences), David A. Muller(Cornell University), Benjamin Liang(The University of Queensland), Andreas Suhrbier(The University of Queensland), Steven T. Anderson(United States Geological Survey), Naphak Modhiran(The University of Queensland), Christopher L. D. McMillan(The University of Queensland), Daniel J Rawle(QIMR Berghofer Medical Research Institute), Ariel Isaacs(The University of Queensland)
Cited by 1
Related Papers
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.
|The Journal of Experimental Medicine|1994|281
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
|Cell|2021|236
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
|Molecular Psychiatry|2022|178
A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses
|Nature Communications|2021|177